What is Viracta Therapeutics Inc's earnings per share (EPS)?

Viracta Therapeutics Inc (VIRX) reported diluted earnings per share of -$1.32 for fiscal year 2023. This represents a -1.5% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Viracta Therapeutics Inc (VIRX) Financials

VIRX

FY2023 annual

Net Income -$51.1M -3.8% YoY

EPS (Diluted) -$1.32 -1.5% YoY

Free Cash Flow -$40.0M -12.8% YoY

Operating Cash Flow -$39.9M -12.5% YoY

Source SEC Filings (10-K/10-Q) Latest period Q3 FY2024, ended Sep 30, 2024 Reported Nov 13, 2024 Currency USD FYE December

Newest figures come from the 10-Q for Q3 FY2024, filed Nov 13, 2024. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the VIRX SEC filings page.

This page shows Viracta Therapeutics Inc (VIRX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI VIRX FY2023 2026-08-30

Viracta’s development-investment model produces persistent losses that closely track cash use as short-term liquidity tightens.

The cash-conversion gap is relatively narrow in FY2023: net loss was -$51.1M and operating cash flow was -$39.9M, so reported earnings closely approximate the cash used by operations rather than being dominated by non-cash effects. Meanwhile, R&D reached $33.4M versus SG&A of $17.3M, indicating development spending—not general administration—is the larger operating commitment.

The balance sheet became less forgiving: FY2023 total assets were $56.7M while total liabilities were $38.4M, leaving liabilities materially closer to the asset base than in FY2022. The current ratio fell from 9.4x to 1.4x, a sharp reduction in near-term working-capital cushion even with no long-term debt.

R&D rose from $23.9M in FY2021 to $33.4M in FY2023, so the narrowing loss cannot be attributed to pulling back on development spending. Net loss moved from -$114.8M to -$51.1M across those years, pointing instead to a change in the broader cost or operating mix while the core investment commitment remained elevated.

Financial Health Signals

Financial health score not available

Viracta Therapeutics Inc does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Partial

2/7

Viracta Therapeutics Inc passes 2 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.

Earnings Quality No Cash Backing

N/A

Viracta Therapeutics Inc reported a net loss of $51.1M while operations used $39.9M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk

N/A

Viracta Therapeutics Inc reported an operating loss of $50.7M against $3.7M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

EBITDA

-$10.1M

YoY+18.4%

QoQ-6.1%

Viracta Therapeutics Inc's EBITDA was -$10.1M in Q3 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 18.4% from the same quarter a year earlier. Against the prior quarter it is down 6.1%.

Net Income

-$10.6M

YoY+16.2%

QoQ-7.4%

Viracta Therapeutics Inc reported -$10.6M in net income in Q3 2024. This represents an increase of 16.2% from the same quarter a year earlier. Against the prior quarter it is down 7.4%.

EPS (Diluted)

-$0.27

YoY+18.2%

QoQ-8.0%

Viracta Therapeutics Inc earned -$0.27 per diluted share (EPS) in Q3 2024. This represents an increase of 18.2% from the same quarter a year earlier. Against the prior quarter it is down 8.0%.

Revenue

Not reported for Q3 2024.

Cash & Balance Sheet

Free Cash Flow

-$7.1M

YoY+33.0%

Viracta Therapeutics Inc recorded an outflow of $7.1M in free cash flow in Q3 2024, representing a cash shortfall after capex. This represents an increase of 33.0% from the same quarter a year earlier.

Cash & Debt

$13.1M

YoY+2.1%

QoQ-6.1%

5Y CAGR-7.8%

10Y CAGR-4.5%

Viracta Therapeutics Inc held $13.1M in cash against $16.9M in long-term debt as of Q3 2024.

Shares Outstanding

40M

YoY+2.9%

QoQ+0.8%

5Y CAGR-18.6%

10Y CAGR-4.3%

Viracta Therapeutics Inc had 40M shares outstanding in Q3 2024. This represents an increase of 2.9% from the same quarter a year earlier. Against the prior quarter it is up 0.8%.

Dividends Per Share

Not reported for Q3 2024.

Margins & Returns

None of these metrics is reported for Q3 2024.

Capital Allocation

R&D Spending

$7.2M

YoY-12.0%

QoQ+9.7%

Viracta Therapeutics Inc invested $7.2M in research and development in Q3 2024. This represents a decrease of 12.0% from the same quarter a year earlier. Against the prior quarter it is up 9.7%.

Capital Expenditures

YoY-100.0%

Viracta Therapeutics Inc reported no capital expenditure in Q3 2024. This represents a decrease of 100.0% from the same quarter a year earlier.

Share Buybacks

Not reported for Q3 2024.

VIRX Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

VIRX quarterly income statement

Metric	TTM	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K	FY1010-K	FY0910-K
Revenue	N/A	N/A	N/A	$40.0M+33233.3%	$120K-94.2%	$2.1M+774.7%	$237K-64.6%	$669K-73.6%	$2.5M-17.2%	$3.1M-46.6%	$5.7M-27.9%	$8.0M+111.9%	$3.8M-24.9%	$5.0M+15051.5%	$33K-99.1%	$3.8M
R&D Expenses	N/A	$33.4M+27.1%	$26.3M+10.1%	$23.9M+77.2%	$13.5M+51.9%	$8.9M-39.3%	$14.6M-32.1%	$21.5M-5.9%	$22.9M-3.5%	$23.7M-14.3%	$27.7M-4.2%	$28.9M-1.0%	$29.2M+29.3%	$22.6M+56.3%	$14.4M+9.0%	$13.2M
SG&A Expenses	N/A	$17.3M-28.8%	$24.3M+57.6%	$15.4M+188.6%	$5.3M+67.4%	$3.2M-71.8%	$11.3M-16.4%	$13.5M-15.9%	$16.1M-13.6%	$18.7M-19.3%	$23.1M+113.2%	$10.8M+18.1%	$9.2M+10.5%	$8.3M+18.5%	$7.0M-9.6%	$7.7M
Operating Income	N/A	-$50.7M-0.2%	-$50.6M+55.7%	-$114.3M-507.4%	-$18.8M+19.2%	-$23.3M+9.4%	-$25.7M+25.3%	-$34.4M+5.6%	-$36.5M+7.2%	-$39.3M+12.7%	-$45.0M-41.8%	-$31.8M+8.2%	-$34.6M-33.8%	-$25.9M-20.8%	-$21.4M-11.8%	-$19.1M
EBITDA	N/A	-$50.2M+0.4%	-$50.4M+55.8%	-$114.1M-507.5%	-$18.8M+19.6%	-$23.4M+9.1%	-$25.7M+25.3%	-$34.4M+5.6%	-$36.4M+7.2%	-$39.3M+12.7%	-$45.0M-41.8%	-$31.8M+8.2%	-$34.6M-34.0%	-$25.8M-21.4%	-$21.3M-13.0%	-$18.8M
Interest Expense	N/A	$3.7M+541.9%	$577K+17.5%	$491K+127.3%	$216K+404.5%	$43K-96.3%	$1.2M-17.3%	$1.4M-18.9%	$1.7M+83.3%	$939K-45.4%	$1.7M-41.1%	$2.9M+57.3%	$1.9M+616.2%	$259K	N/A	N/A
Income Tax	N/A	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	N/A
Net Income	N/A	-$51.1M-3.8%	-$49.2M+57.1%	-$114.8M-503.5%	-$19.0M-40.3%	-$13.6M+49.1%	-$26.6M+24.9%	-$35.5M+6.7%	-$38.0M-3.7%	-$36.7M+14.7%	-$43.0M-24.3%	-$34.6M+21.3%	-$44.0M-118.2%	-$20.1M+18.1%	-$24.6M+38.9%	-$40.2M
EPS (Basic)	N/A	-$1.32-1.5%	-$1.30+63.9%	-$3.60	N/A	N/A	N/A	-$1.45+40.1%	-$2.42+19.9%	-$3.02+29.8%	-$4.30-551.5%	-$0.66+27.5%	-$0.91	N/A	N/A	N/A
EPS (Diluted)	-$1.10	-$1.32-1.5%	-$1.30+63.9%	-$3.60	N/A	N/A	N/A	-$1.45	-$2.42	-$3.02+33.9%	-$4.57	-$0.66+27.5%	-$0.91	N/A	N/A	N/A
Diluted Shares (Avg)	N/A	39M+2.2%	38M+18.6%	32M	N/A	N/A	N/A	25M	16M	12M+18.6%	10M	52M+8.5%	48M	N/A	N/A	N/A

Metric	Q3'2410-Q	Q2'2410-Q	Q1'2410-Q	Q4'2310-Q	Q3'2310-Q	Q2'2310-Q	Q1'2310-Q	Q4'2210-K
R&D Expenses	$7.2M-12.0%	$6.5M-20.1%	$10.0M+30.9%	N/A	$8.2M+14.3%	$8.2M+29.6%	$7.6M+24.8%	N/A
SG&A Expenses	$3.0M-30.4%	$3.0M-28.5%	$3.9M-14.8%	N/A	$4.3M-60.5%	$4.3M+1.7%	$4.6M+6.1%	N/A
Operating Income	-$10.2M+18.4%	-$9.6M+23.0%	-$13.9M-13.7%	N/A	-$12.5M+31.0%	-$12.4M-18.5%	-$12.2M-17.0%	N/A
EBITDA	-$10.1M+18.4%	-$9.5M+23.0%	-$13.8M-13.9%	N/A	-$12.3M+31.5%	-$12.3M-18.0%	-$12.1M-16.4%	N/A
Interest Expense	$679K-28.8%	$697K-24.3%	$858K-2.5%	N/A	$953K+585.6%	$921K+625.2%	$880K+609.7%	N/A
Net Income	-$10.6M+16.2%	-$9.8M+21.3%	-$9.1M+25.1%	N/A	-$12.6M+29.0%	-$12.5M-18.0%	-$12.2M-15.8%	N/A
EPS (Basic)	-$0.27+18.2%	-$0.25+21.9%	-$0.23+28.1%	-$0.35-29.6%	-$0.33+29.8%	-$0.32-14.3%	-$0.32-14.3%	-$0.27-68.8%
EPS (Diluted)	-$0.27+18.2%	-$0.25+21.9%	-$0.23+28.1%	-$0.35-29.6%	-$0.33+29.8%	-$0.32-214.3%	-$0.32-14.3%	-$0.27
Diluted Shares (Avg)	40M+2.3%	39M+2.2%	39M+2.2%	N/A	39M+2.6%	39M+2.6%	38M+2.5%	N/A

Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Income Tax.

VIRX Balance Sheet

VIRX quarterly balance sheet

Metric	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K	FY1010-K	FY0910-K
Total Assets	$56.7M-40.9%	$96.0M-11.6%	$108.6M+124.7%	$48.3M+161.9%	$18.4M+20.4%	$15.3M-55.4%	$34.3M-20.6%	$43.2M-8.0%	$47.0M+6.2%	$44.2M+9.2%	$40.5M-44.5%	$73.0M+59.2%	$45.9M-16.4%	$54.9M	N/A
Current Assets	$55.0M-41.4%	$93.7M-10.9%	$105.3M+123.0%	$47.2M+157.9%	$18.3M+20.4%	$15.2M-53.8%	$32.9M-23.8%	$43.2M-8.0%	$47.0M+6.3%	$44.2M+9.2%	$40.5M-44.5%	$72.9M+59.7%	$45.7M-16.5%	$54.7M	N/A
Cash & Equivalents	$12.3M-66.5%	$36.8M-64.5%	$103.6M+119.9%	$47.1M+158.5%	$18.2M+33.0%	$13.7M-49.2%	$27.0M+234.9%	$8.1M-70.0%	$26.9M+21.2%	$22.2M+46.7%	$15.1M+1.2%	$14.9M+60.5%	$9.3M-34.5%	$14.2M+234.0%	$4.3M
Short-Term Investments	$41.4M-23.8%	$54.3M	$0	$0-100.0%	$16.4M	$0-100.0%	$4.8M-86.2%	$34.5M+76.7%	$19.5M-6.0%	$20.8M-14.0%	$24.2M-57.1%	$56.3M+61.7%	$34.8M-11.2%	$39.2M	$0
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$38.4M+10.0%	$34.9M+146.0%	$14.2M-85.0%	$94.5M+101.8%	$46.8M+50.2%	$31.2M+143.8%	$12.8M-42.4%	$22.2M+13.3%	$19.6M-35.6%	$30.4M-34.8%	$46.7M-23.5%	$61.1M+242.1%	$17.8M+41.5%	$12.6M	N/A
Current Liabilities	$38.4M+283.3%	$10.0M+10.2%	$9.1M+44.6%	$6.3M+162.5%	$2.4M-78.9%	$11.3M-10.7%	$12.7M+15.9%	$10.9M-42.4%	$19.0M-31.9%	$27.9M-17.9%	$34.0M+7.0%	$31.7M+278.6%	$8.4M-33.3%	$12.6M	N/A
Non-Current Liabilities	$0-100.0%	$24.9M+388.1%	$5.1M-94.2%	$88.2M+98.6%	$44.4M+123.7%	$19.9M+17633.3%	$112K-99.0%	$11.3M+1747.7%	$610K-76.2%	$2.6M-79.9%	$12.7M-56.6%	$29.3M+209.7%	$9.5M+19620.8%	$48K	N/A
Long-Term Debt	$0-100.0%	$24.9M+416.2%	$4.8M+16.0%	$4.2M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$18.3M-70.0%	$61.1M-35.3%	$94.4M+304.3%	-$46.2M-62.8%	-$28.4M-79.0%	-$15.9M-173.6%	$21.5M+2.5%	$21.0M-23.3%	$27.4M+98.5%	$13.8M+323.2%	-$6.2M-151.7%	$12.0M-57.3%	$28.0M-33.7%	$42.2M+1950.8%	$2.1M
Retained Earnings	-$265.9M-23.8%	-$214.9M-29.7%	-$165.7M-225.4%	-$50.9M-59.6%	-$31.9M+95.2%	-$659.5M-4.2%	-$632.9M-5.9%	-$597.4M-6.8%	-$559.4M-7.0%	-$522.7M-9.0%	-$479.7M-7.8%	-$445.1M-11.0%	-$401.1M-5.3%	-$381.0M	N/A

Metric	Q3'2410-Q	Q2'2410-Q	Q1'2410-Q	Q4'2310-Q	Q3'2310-Q	Q2'2310-Q	Q1'2310-Q	Q4'2210-K
Total Assets	$22.0M-66.9%	$31.3M-59.2%	$41.3M-51.8%	$56.7M-40.9%	$66.4M-19.2%	$76.9M-13.8%	$85.8M-12.8%	$96.0M-11.6%
Current Assets	$21.8M-66.2%	$31.1M-58.3%	$41.0M-50.9%	$55.0M-41.4%	$64.4M-19.1%	$74.6M-13.7%	$83.4M-12.5%	$93.7M-10.9%
Cash & Equivalents	$13.1M+2.1%	$14.0M-2.2%	$12.1M-33.4%	$12.3M-66.5%	$12.9M-45.2%	$14.3M-82.5%	$18.1M-80.4%	$36.8M-64.5%
Short-Term Investments	$8.0M-84.0%	$16.0M-72.6%	$27.5M-55.8%	$41.4M-23.8%	$50.1M-6.5%	$58.6M+3649.9%	$62.2M	$54.3M
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$28.6M-21.6%	$28.7M-20.6%	$30.3M-12.7%	$38.4M+10.0%	$36.4M+153.2%	$36.1M+196.9%	$34.7M+171.2%	$34.9M+146.0%
Current Liabilities	$28.6M-21.6%	$28.7M+88.3%	$30.3M+159.6%	$38.4M+283.3%	$36.4M+288.1%	$15.2M+110.7%	$11.7M+50.1%	$10.0M+10.2%
Non-Current Liabilities	$0	$0-100.0%	$0-100.0%	$0-100.0%	$0-100.0%	$20.9M+323.1%	$23.0M+358.8%	$24.9M+388.1%
Long-Term Debt	$16.9M	$18.7M-9.8%	$18.7M-18.2%	$0-100.0%	$0-100.0%	$20.8M+327.8%	$22.8M+371.7%	$24.9M+416.2%
Total Equity	-$6.6M-122.1%	$2.7M-93.5%	$11.1M-78.3%	$18.3M-70.0%	$30.0M-55.7%	$40.8M-47.0%	$51.1M-40.3%	$61.1M-35.3%
Retained Earnings	-$295.5M-17.2%	-$284.9M-18.9%	-$275.1M-21.1%	-$265.9M-23.8%	-$252.2M-23.3%	-$239.6M-28.2%	-$227.1M-28.9%	-$214.9M-29.7%

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill.

VIRX Cash Flow Statement

VIRX quarterly cash flow statement

Metric	TTM	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K	FY1010-K	FY0910-K
Operating Cash Flow	-$34.8M	-$39.9M-12.5%	-$35.5M-88.1%	-$18.9M-17.4%	-$16.1M-54.7%	-$10.4M+57.5%	-$24.4M+32.5%	-$36.1M+2.2%	-$37.0M+4.6%	-$38.7M+10.3%	-$43.2M-15.4%	-$37.4M-251.7%	-$10.6M+53.4%	-$22.8M-17.8%	-$19.4M+4.0%	-$20.2M
Depreciation & Amortization	N/A	$492K+134.3%	$210K+18.0%	$178K+456.3%	$32K+145.7%	-$70K-877.8%	$9K0.0%	$9K-18.2%	$11K-59.3%	$27K-6.9%	$29K+45.0%	$20K-35.5%	$31K-44.6%	$56K-62.7%	$150K-56.1%	$342K
Stock-Based Compensation	N/A	$7.6M-43.5%	$13.5M+144.5%	$5.5M+1492.5%	$348K-44.6%	$628K-76.2%	$2.6M-13.1%	$3.0M-36.7%	$4.8M-24.5%	$6.3M+2.0%	$6.2M+60.1%	$3.9M+42.6%	$2.7M+96.3%	$1.4M+58.3%	$877K-34.6%	$1.3M
Capital Expenditures	N/A	$138K+206.7%	$45K-82.1%	$252K+358.2%	$55K	N/A	N/A	$26K	N/A	N/A	$48K	N/A	N/A	$15K-76.6%	$64K+966.7%	$6K
Free Cash Flow	N/A	-$40.0M-12.8%	-$35.5M-85.8%	-$19.1M-18.6%	-$16.1M	N/A	N/A	-$36.2M	N/A	N/A	-$43.2M	N/A	N/A	-$22.9M-17.5%	-$19.4M+3.7%	-$20.2M
Investing Cash Flow	$43.3M	$15.0M+127.8%	-$53.9M-517.9%	$12.9M+23538.2%	-$55K	$0-100.0%	$4.8M-83.9%	$29.7M	N/A	N/A	N/A	$32.2M+250.7%	-$21.4M-611.5%	$4.2M+110.7%	-$39.1M-931.8%	$4.7M
Financing Cash Flow	-$8.3M	$438K-98.1%	$22.5M-63.9%	$62.4M+38.8%	$45.0M+83.0%	$24.6M+287.6%	$6.3M-74.9%	$25.3M	N/A	N/A	N/A	$5.4M-85.7%	$37.6M+173.8%	$13.7M-79.9%	$68.4M+408.9%	$13.4M

Metric	Q3'2410-Q	Q2'2410-Q	Q1'2410-Q	Q4'2310-Q	Q3'2310-Q	Q2'2310-Q	Q1'2310-Q	Q4'2210-K
Operating Cash Flow	-$7.1M+32.7%	-$9.8M-23.0%	-$7.8M+30.8%	-$10.0M-26.9%	-$10.5M-47.2%	-$8.0M+11.6%	-$11.3M+0.2%	-$7.9M-9.6%
Depreciation & Amortization	$110K-14.1%	$96K-19.3%	$110K-9.8%	$123K+115.8%	$128K+184.4%	$119K+120.4%	$122K+125.9%	$57K-3.4%
Stock-Based Compensation	$1.3M-29.6%	$1.4M-30.4%	$1.8M-13.0%	N/A	$1.8M-76.8%	$2.0M+1.1%	$2.1M+19.2%	N/A
Capital Expenditures	$0-100.0%	N/A	N/A	$0	-$51K+5000.0%	N/A	N/A	$0-100.0%
Free Cash Flow	-$7.1M+33.0%	N/A	N/A	-$10.0M-26.9%	-$10.6M-47.9%	N/A	N/A	-$7.9M-9.3%
Investing Cash Flow	$8.2M-10.3%	$11.7M+194.0%	$14.2M+293.1%	$9.3M+4666.5%	$9.1M+117.5%	$4.0M+347.8%	-$7.3M	-$203K-968.4%
Financing Cash Flow	-$1.9M	$43K-78.9%	-$6.6M-41337.5%	$218K-99.0%	$0-100.0%	$204K+750.0%	$16K+100.0%	$21.4M+10857.3%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

VIRX Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

VIRX quarterly financial ratios

Metric	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K	FY1010-K	FY0910-K
Operating Margin	N/A	N/A	-285.7%	-15679.2%	-1123.4%	-10848.1%	-5144.8%	-1437.7%	-1284.0%	-785.5%	-399.4%	-921.8%	-517.3%	-64863.6%	-509.0%
Net Margin	N/A	N/A	-286.9%	-15847.5%	-654.1%	-11230.0%	-5300.1%	-1499.3%	-1198.2%	-750.0%	-434.9%	-1170.8%	-402.8%	-74506.1%	-1069.3%
Return on Equity	-278.7%-198.2pp	-80.5%+41.1pp	-121.6%	N/A	N/A	N/A	-164.6%+16.3pp	-180.9%-47.0pp	-133.9%+177.7pp	-311.6%	N/A	-367.6%-295.7pp	-71.9%-13.7pp	-58.2%+1894.5pp	-1952.7%
Return on Assets	-90.1%-38.8pp	-51.2%+54.5pp	-105.7%-66.3pp	-39.4%+34.1pp	-73.5%+100.2pp	-173.7%-70.4pp	-103.3%-15.3pp	-87.9%-9.9pp	-78.0%+19.2pp	-97.2%-11.8pp	-85.4%-25.2pp	-60.2%-16.3pp	-43.9%+0.9pp	-44.8%	N/A
Current Ratio	1.43-7.9x	9.36-2.2x	11.59+4.1x	7.51-0.1x	7.64+6.3x	1.34-1.3x	2.60-1.4x	3.95+1.5x	2.47+0.9x	1.59+0.4x	1.19-1.1x	2.30-3.1x	5.45+1.1x	4.35	N/A
Debt-to-Equity	0.00-0.4x	0.41+0.4x	0.05	N/A	N/A	N/A	0.59-0.5x	1.06+0.3x	0.72-1.5x	2.21	N/A	5.11+4.5x	0.64+0.3x	0.30	N/A
Asset Turnover	N/A	N/A	0.37+0.4x	0.00-0.1x	0.11+0.1x	0.020.0x	0.020.0x	0.060.0x	0.07-0.1x	0.13-0.1x	0.20+0.1x	0.05-0.1x	0.11+0.1x	0.00	N/A
FCF Margin	N/A	N/A	-47.8%	-13424.2%	N/A	N/A	-5406.3%	N/A	N/A	-753.9%	N/A	N/A	-457.0%	-58921.2%	-536.7%

Metric	Q3'2410-Q	Q2'2410-Q	Q1'2410-Q	Q4'2310-Q	Q3'2310-Q	Q2'2310-Q	Q1'2310-Q	Q4'2210-K
Return on Equity	N/A	-368.0%-337.4pp	-82.5%-58.6pp	N/A	-42.0%-15.8pp	-30.6%-16.9pp	-23.9%-11.6pp	N/A
Return on Assets	-48.1%-29.1pp	-31.4%-15.1pp	-22.1%-7.9pp	N/A	-19.0%+2.6pp	-16.2%-4.4pp	-14.2%-3.5pp	N/A
Current Ratio	0.76-1.0x	1.08-3.8x	1.35-5.8x	1.43-7.9x	1.77-6.7x	4.90-7.1x	7.16-5.1x	9.36-2.2x
Debt-to-Equity	N/A	7.02+6.5x	1.69+1.2x	0.00-0.4x	0.00-0.1x	0.51+0.4x	0.45+0.4x	0.41+0.4x

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Viracta Therapeutics Inc VIRX	FY2023	N/A	-$51.1M	N/A	N/A	—
Bio-Path Hldgs Inc BPTH	FY2024	N/A	-$9.9M	N/A	$4.7M	—

Where Viracta Therapeutics Inc Ranks

Frequently Asked Questions

Is Viracta Therapeutics Inc profitable?

No, Viracta Therapeutics Inc (VIRX) reported a net income of -$51.1M in fiscal year 2023.

What is Viracta Therapeutics Inc's EBITDA?

Viracta Therapeutics Inc (VIRX) had EBITDA of -$50.2M in fiscal year 2023, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Viracta Therapeutics Inc have?

As of fiscal year 2023, Viracta Therapeutics Inc (VIRX) had $12.3M in cash and equivalents against $0 in long-term debt.

What is Viracta Therapeutics Inc's return on equity (ROE)?

Viracta Therapeutics Inc (VIRX) has a return on equity of -278.7% for fiscal year 2023, measuring how efficiently the company generates profit from shareholder equity.

What is Viracta Therapeutics Inc's free cash flow?

Viracta Therapeutics Inc (VIRX) recorded an outflow of $40.0M in free cash flow during fiscal year 2023. This represents a -12.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Viracta Therapeutics Inc's operating cash flow?

Viracta Therapeutics Inc (VIRX) recorded an outflow of $39.9M in operating cash flow during fiscal year 2023, representing cash used by core business activities.

What are Viracta Therapeutics Inc's total assets?

Viracta Therapeutics Inc (VIRX) had $56.7M in total assets as of fiscal year 2023, including both current and long-term assets.

What are Viracta Therapeutics Inc's capital expenditures?

Viracta Therapeutics Inc (VIRX) invested $138K in capital expenditures during fiscal year 2023, funding long-term assets and infrastructure.

How much does Viracta Therapeutics Inc spend on research and development?

Viracta Therapeutics Inc (VIRX) invested $33.4M in research and development during fiscal year 2023.

How many shares does Viracta Therapeutics Inc have outstanding?

Viracta Therapeutics Inc (VIRX) had 39M shares outstanding as of fiscal year 2023.

What is Viracta Therapeutics Inc's current ratio?

Viracta Therapeutics Inc (VIRX) had a current ratio of 1.43 as of fiscal year 2023, which is considered adequate.

What is Viracta Therapeutics Inc's debt-to-equity ratio?

Viracta Therapeutics Inc (VIRX) had a debt-to-equity ratio of 0.00 as of fiscal year 2023, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Viracta Therapeutics Inc's return on assets (ROA)?

Viracta Therapeutics Inc (VIRX) had a return on assets of -90.1% for fiscal year 2023, measuring how efficiently the company uses its assets to generate profit.

How does Viracta Therapeutics Inc's liquidity compare with its operating cash outflow?

At the end of fiscal year 2023, Viracta Therapeutics Inc (VIRX) held $53.7M in cash, cash equivalents and investments, and reported an operating cash outflow of $39.9M over that year. Dividing the one by the other, the reported balance equals about 16 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is Viracta Therapeutics Inc's Piotroski F-Score?

Viracta Therapeutics Inc (VIRX) has a Piotroski F-Score of 2 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Viracta Therapeutics Inc's earnings high quality?

Viracta Therapeutics Inc (VIRX) reported a net loss of $51.1M while operations used $39.9M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Viracta Therapeutics Inc cover its interest payments?

Viracta Therapeutics Inc (VIRX) reported an operating loss of $50.7M against $3.7M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.